Immuno-oncology therapy associated thromboembolic events in metastatic renal cell carcinoma

The relationship between thromboembolic events (TEs) and immune-oncology (IO) agents in patients with metastatic renal cell carcinoma (mRCC) with inferior-vena-cava (IVC) thrombus has not been explored despite conferring significant morbidity. A late 30s female is diagnosed with mRCC with a level-II...

Descripción completa

Detalles Bibliográficos
Autores principales: Alhamdani, Zein, Alberto, Matthew, Ischia, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199195/
https://www.ncbi.nlm.nih.gov/pubmed/37215941
http://dx.doi.org/10.1016/j.eucr.2023.102420
Descripción
Sumario:The relationship between thromboembolic events (TEs) and immune-oncology (IO) agents in patients with metastatic renal cell carcinoma (mRCC) with inferior-vena-cava (IVC) thrombus has not been explored despite conferring significant morbidity. A late 30s female is diagnosed with mRCC with a level-II IVC thrombus after presenting with back pain. Two weeks post initiation of immunotherapy, she re-presented with bilateral sub-massive pulmonary emboli requiring IVC and pulmonary thrombectomy. This case exposes a potential relationship between mRCC and IVC thrombus with IO agents that creates a critically hypercoagulable state. This issue requires further investigation given the apparent under-reporting of TEs in these patients.

Ejemplares similares